Immunovant Sciences GmbH — Sponsor Intelligence | 15 EU Trials

Filter these 15 trials by condition, phase, country and more.

Open in Search →

15 Registered trials

6 Recruiting

9 Completed trials

22 Countries active

2 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 5 Phase II: 10

Oversight events:

14 temporary halts 2 urgent safety measures across 3 trials

View oversight register →

100%

9 of 9 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

IMEROPRUBART 8 BATOCLIMAB 7

All trials

15 total

A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Phase II 11 countries IMEROPRUBART
Efficacy and Safety of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity Recruiting

2025-520831-18-00 Phase II 7 countries IMEROPRUBART
A Phase 2b Study of IMVT-1402 Treatment in CIDP Recruiting

2024-517614-14-00 Phase II 19 countries IMEROPRUBART
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting

2025-521920-31-00 Phase II 9 countries IMEROPRUBART
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting

2024-515979-35-00 Phase III 9 countries IMEROPRUBART
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Grave’s Disease Recruiting

2024-516020-33-00 Phase II 6 countries IMEROPRUBART
A Phase 2b Study to Assess IMVT-1402 in Participants with Cutaneous Lupus Erythematosus Ended

2024-516745-39-00 Phase II 5 countries IMEROPRUBART
A Phase 2b to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With ACPA-Positive Rheumatoid Arthritis Ended

2024-515973-82-00 Phase II 7 countries IMEROPRUBART
A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP Ended

2024-518364-12-00 Phase II 10 countries BATOCLIMAB
Extension Study to Assess Batoclimab in Participants with TED. Ended

2024-512650-21-00 Phase III 7 countries BATOCLIMAB
Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease. Ended

2024-512648-45-00 Phase III 3 countries BATOCLIMAB
Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended

2024-512646-42-00 Phase II 14 countries BATOCLIMAB
Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones. Ended

2024-512647-23-00 Phase II 1 country BATOCLIMAB
Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease Ended

2024-512649-18-00 Phase III 6 countries BATOCLIMAB
Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasth… Ended

2024-512258-91-00 Phase III 6 countries BATOCLIMAB

Showing 1–15 of 15 trials

← All sponsors A–Z